Regarding the comparison between PD-1 and PD-L1 inhibitor, except for a similar incidence rate of severe pneumonia, the incidence rate of other respiratory adverse reactions was higher with PD-1 inhibitor treatment(Supplementary Fig. 5). This evidence concerns the gene CD274 and pneumonia.